glp-1 molecular weight RCSB PDB PDB-101: Molecule of the Month:

In a casecontrol design, patients electing to receive GLP-1-RA therapy in addition to UCWM were included based on the following inclusion criteria: definite IIH according to the modified Friedman criteria [17], BMI \(\ge\) 30 kg/m 2 , and a follow-up of \(\ge\) 6 months

The benefits of these medications for glycaemic control and cardiovascular risk reduction generally outweigh the potential pancreatic risks in appropriately selected patients

Postgrad Med J (1996) 72:6823

A half-life is the time it takes for the concentration of a substance in your body to reduce by half

Comprehensive analysis of the safety of semaglutide in type 2 diabetes: a meta-analysis of the SUSTAIN and PIONEER trials

Farxiga is an SGLT2 inhibitor an oral medication that lowers blood glucose levels by blocking glucose reabsorption in the kidneys, causing sugar to be eliminated through urine